1.Carcinoma expleomorphic adenoma of lacrimal gland.
Jun Hee BYEON ; Yong Nam CHO ; Jong Won RHIE ; Jong Kun LEE
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1998;25(4):644-648
Based on the histopathologic findings of the lacrimal gland tumor, the lesion is classified as either epithelial or nonepithelial tumor. 22% of lacrimal gland lesions were primary epithelial neoplasm. 4%of epithelial tumor of lacrimal glands were primary malignant tumor. Squamous cell carcinoma arising from pleomorphic adenoma of lacrimal gland is a very rare(0.4%). Inspite of surgical intervention, postoperative radiation and chemotherapy, the mortality and recurrence rate of the carcinoma ex pleomorphic adenoma of lacrimal gland is very high. We report a case of squamous cell carcinoma ex pleomorphic adenoma of lacrimal gland, which was completely removed via lateral orbitotomy with bicoronal incision and had no major complication or recurrence.
Adenoma*
;
Adenoma, Pleomorphic
;
Carcinoma, Squamous Cell
;
Drug Therapy
;
Lacrimal Apparatus*
;
Mortality
;
Neoplasms, Glandular and Epithelial
;
Recurrence
2.Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Maria LEE ; Min Young CHANG ; Hanna YOO ; Kyung Eun LEE ; Doo Byung CHAY ; Hanbyoul CHO ; Sunghoon KIM ; Young Tae KIM ; Jae Hoon KIM
Yonsei Medical Journal 2016;57(3):580-587
PURPOSE: To determine the most powerful cancer antigen 125 (CA125)-related prognostic factor for advanced epithelial ovarian cancer (EOC) and to identify cut-off values that distinguish patients with a poor prognosis from those with a good prognosis. MATERIALS AND METHODS: We included 223 patients who received staging laparotomy and were diagnosed with stage IIC-IV serous EOC. Cox regression analysis was used to determine the most significant prognostic factor among the following variables: serum CA125 before surgery and after the first, second, and sixth cycles of chemotherapy; the nadir CA125 value; the relative percentage change in CA125 levels after the first and second cycles of chemotherapy compared to baseline CA125; CA125 half-life; time to nadir; and time to normalization of the CA125 level. RESULTS: The CA125 level after the first chemotherapy cycle was the most significant independent prognostic factor for overall survival (OS). Time to normalization (p=0.028) and relative percentage change between CA125 levels at baseline and after the first chemotherapy cycle (p=0.021) were additional independent prognostic factors in terms of OS. The CA125 level after the first chemotherapy cycle (p=0.001) and time to normalization (p<0.001) were identified as independent prognostic factors for progression free survival (PFS). CONCLUSION: Among well-established CA125-related prognostic factors, serum CA125 levels after the first cycle of chemotherapy and time to normalization were the most significant prognostic factors for both OS and PFS.
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/*therapeutic use
;
CA-125 Antigen/*blood/metabolism
;
Disease-Free Survival
;
Female
;
Humans
;
Middle Aged
;
Neoplasm Staging
;
Neoplasms, Glandular and Epithelial/*blood/*drug therapy/mortality
;
Ovarian Neoplasms/*blood/*drug therapy/mortality
;
Prognosis
;
Regression Analysis
3.Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy.
Yong Soon KWON ; Joo Hyun NAM ; Dae Yeon KIM ; Dae Shik SUH ; Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM
Journal of Korean Medical Science 2009;24(4):679-683
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.
Altretamine/*therapeutic use
;
Antineoplastic Agents, Alkylating/*therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Disease-Free Survival
;
Female
;
Humans
;
Middle Aged
;
Neoplasm Staging
;
Neoplasms, Glandular and Epithelial/*drug therapy/mortality
;
Ovarian Neoplasms/*drug therapy/mortality
;
Retrospective Studies
4.Effect of progesterone combined with chemotherapy on epithelial ovarian cancer.
Chinese Medical Journal 2003;116(3):388-391
OBJECTIVETo identify an effective auxiliary therapy for epithelial ovarian cancer.
METHODSProgesterone acetate given at 250 mg intramuscularly twice a week for 1 month followed by increased administration to 500 mg intramuscularly every two weeks for 3 years was used in combination with platinum based chemotherapy to treat patients with epithelial ovarian cancer as a first-line therapy. Prognoses of the patients receiving progesterone combined with chemotherapy (progesterone group) and those receiving chemotherapy only (control group) were compared.
RESULTSThree-year recurrence and survival conditions of the progesterone and control groups were as follows. Stage Ia: no patient relapsed or died in either group. Stage Ib-Ic: three-year recurrence rates were 14.2% and 37.5%, respectively (P = 0.2845); three-year survival rates were 92.3% and 87.5% (P = 0.7221). Stage II: 1 patient relapsed and died among the 3 patients in the progesterone group; among the 4 patients in the control group, 1 patient relapsed, none died. Stage III: three-year recurrence rates were 30.8% and 64.3%, respectively (P = 0.1170); three-year survival rates were 85.7% and 42.9%, respectively (P = 0.005). Stage IV: 4 patients relapsed and 1 patient died among the 7 patients in the progesterone group; both the patients in the control group relapsed and died.
CONCLUSIONSThe results indicated that progesterone combined with platinum based chemotherapy as a first-line therapy may improve the prognosis of advanced epithelial ovarian cancer, but would not change the prognosis of early stage epithelial ovarian cancer.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial ; drug therapy ; mortality ; pathology ; Ovarian Neoplasms ; drug therapy ; mortality ; pathology ; Progesterone ; administration & dosage ; Survival Rate